With its acquisition of DNA Therapeutics, Onxeo has added a clinical stage signal-interfering DNA (siDNA) technology, which has already been tested in a Phase I trial for melanoma and demonstrated an attractive safety profile and preliminary anti-tumour activity, when administered locally. The new product called AsiDNA is a first-in-class and differentiated asset in the up-and-coming DNA repair interference field. Our increased valuation of Onxeo is €343m.
